Innate Pharma Provides Update on Lacutamab Clinical Program
MARSEILLE, France, October 05, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the lacutamab IND leading to a pause in new patient enrollment to the Company’s ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL). The partial clinical hold follows one fatal case of hemophagocytic lymphoh...
United States Henry Wheeler Mondher Mahjoubi Exchange Commission French Financial Markets Authority European Union
Source: yahoo.com